Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

Long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high r ...

Wells Fargo has downgraded Editas (EDIT) to equal weight, citing concerns about the potential positioning of reni-cel. Read ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the American Society of Hematology meeting in San Diego.

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

In a report released on December 10, Mitchell Kapoor from H.C. Wainwright maintained a Buy rating on Metagenomi, Inc. (MGX – Research Report), ...